Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma <i>In Situ</i>
This study provides evidence of increased use of low-dose tamoxifen in a prevention setting, particularly among younger women and those with less advanced breast lesions. Further research is needed to understand how to incorporate low-dose tamoxifen into patient-provider discussions to improve chemoprevention decision-making.
Authors
- Rita Kukafka (ORCID: https://orcid.org/0000-0002-0960-7576)
- Julia E. McGuinness (ORCID: https://orcid.org/0000-0001-5292-1440)
- Peter J. Zeiger (ORCID: https://orcid.org/0000-0002-5923-7075)
- Margaret H. Kyle (ORCID: https://orcid.org/0000-0003-0771-827X)
- M. Deshmukh
- Vicky Ro (ORCID: https://orcid.org/0000-0002-3502-2707)
- Alissa M. Michel (ORCID: https://orcid.org/0000-0003-0829-9804)
- KD Crew
- Romi Eli (ORCID: https://orcid.org/0009-0002-8803-1081)
Institutions
- Columbia University Irving Medical Center (US)
- Columbia University (US)
Publication Details
- Journal
- Cancer Prevention Research
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1158/1940-6207.capr-25-0247
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00